表紙:世界の動脈瘤性くも膜下出血治療薬市場:世界の機会分析と業界予測
市場調査レポート
商品コード
633194

世界の動脈瘤性くも膜下出血治療薬市場:世界の機会分析と業界予測

Aneurysmal Subarachnoid Hemorrhage Drugs Market by Drug Class (Opioid Analgesic, Calcium Channel Blocker, Anticonvulsant, Stool Softener, Osmotic Agent/Diuretic, and Other Drugs) - Global Opportunity Analysis and Industry Forecast, 2017-2023

出版日: | 発行: Allied Market Research | ページ情報: 英文 142 Pages | 納期: 2~3営業日

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=114.84円
世界の動脈瘤性くも膜下出血治療薬市場:世界の機会分析と業界予測
出版日: 2018年04月01日
発行: Allied Market Research
ページ情報: 英文 142 Pages
納期: 2~3営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

当レポートでは、世界の動脈瘤性くも膜下出血治療薬市場について調査し、市場の概要と薬剤クラス、地域別動向、および市場に参入する企業のプロファイルなどをまとめています。

第1章 イントロダクション

第2章 エグゼクティブサマリー

第3章 市場概要

  • 市場定義と範囲
  • 主な調査結果
  • 主要企業のポジショニング
  • 市場動向
    • 促進因子
    • 阻害因子
    • 機会
    • 影響分析

第4章 薬剤クラス別市場

  • 概要
  • オピオイド鎮痛剤
  • カルシウムチャネル阻害剤
  • 抗痙攣剤
  • 軟下剤
  • 浸透圧性薬剤/利尿剤
  • その他

第5章 地域別

  • 概要
  • 北米
  • 欧州
  • アジア太平洋地域
  • ラテンアメリカ

第7章 企業プロファイル

  • Arbor Pharmaceuticals Inc.
  • Edge Therapeutics, Inc.
  • Johnson & Johnson
  • Mylan N.V.
  • Orexo AB
  • Pfizer Inc.
  • Purdue Pharma L.P.
  • Pharmaxis, Ltd.
  • Sun Pharmaceutical Industries Ltd.
  • Teva Pharmaceutical Industries Ltd.

図表

図表

List of Tables

  • TABLE 01. RISK FOR SUBARACHNOID HEMORRHAGE BASED ON SMOKING LEVEL

TABLE 02. PATIENTS TREATED, BY DRUG CLASS, 2015-2017

TABLE 03. GLOBAL ANEURYSMAL SUBARACHNOID HEMORRHAGE DRUGS MARKET, BY DRUG CLASS, 2016-2023 ($THOUSAND)

TABLE 04. OPIOID ANALGESICS MARKET, BY REGION, 2016-2023 ($THOUSAND)

TABLE 05. CALCIUM CHANNEL BLOCKERS MARKET, BY REGION, 2016-2023 ($THOUSAND)

TABLE 06. ANTICONVULSANTS MARKET, BY REGION, 2016-2023 ($THOUSAND)

TABLE 07. STOOL SOFTENERS MARKET, BY REGION, 2016-2023 ($THOUSAND)

TABLE 08. OSMOTIC AGENTS/DIURETICS MARKET, BY REGION, 2016-2023 ($THOUSAND)

TABLE 09. OTHER DRUGS MARKET, BY REGION, 2016-2023 ($THOUSAND)

TABLE 10. ANEURYSMAL SUBARACHNOID HEMORRHAGE DRUGS MARKET, BY REGION, 2016-2023 ($THOUSAND)

TABLE 11. NORTH AMERICA ANEURYSMAL SUBARACHNOID HEMORRHAGE DRUGS MARKET, BY COUNTRY, 2016-2023 ($THOUSAND)

TABLE 12. U.S. ANEURYSMAL SUBARACHNOID HEMORRHAGE DRUGS MARKET, BY DRUG CLASS, 2016-2023 ($THOUSAND)

TABLE 13. CANADA ANEURYSMAL SUBARACHNOID HEMORRHAGE DRUGS MARKET, BY DRUG CLASS, 2016-2023 ($THOUSAND)

TABLE 14. MEXICO ANEURYSMAL SUBARACHNOID HEMORRHAGE DRUGS MARKET, BY DRUG CLASS, 2016-2023 ($THOUSAND)

TABLE 15. NORTH AMERICA ANEURYSMAL SUBARACHNOID HEMORRHAGE DRUGS MARKET, BY DRUG CLASS, 2016-2023 ($THOUSAND)

TABLE 16. EUROPE ANEURYSMAL SUBARACHNOID HEMORRHAGE DRUGS MARKET, BY COUNTRY, 2016-2023 ($THOUSAND)

TABLE 17. GERMANY ANEURYSMAL SUBARACHNOID HEMORRHAGE DRUGS MARKET, BY DRUG CLASS, 2016-2023 ($THOUSAND)

TABLE 18. FRANCE ANEURYSMAL SUBARACHNOID HEMORRHAGE DRUGS MARKET, BY DRUG CLASS, 2016-2023 ($THOUSAND)

TABLE 19. UK ANEURYSMAL SUBARACHNOID HEMORRHAGE DRUGS MARKET, BY DRUG CLASS, 2016-2023 ($THOUSAND)

TABLE 20. ITALY ANEURYSMAL SUBARACHNOID HEMORRHAGE DRUGS MARKET, BY DRUG CLASS, 2016-2023 ($THOUSAND)

TABLE 21. SPAIN ANEURYSMAL SUBARACHNOID HEMORRHAGE DRUGS MARKET, BY DRUG CLASS, 2016-2023 ($THOUSAND)

TABLE 22. REST OF EUROPE ANEURYSMAL SUBARACHNOID HEMORRHAGE DRUGS MARKET, BY DRUG CLASS, 2016-2023 ($THOUSAND)

TABLE 23. EUROPE ANEURYSMAL SUBARACHNOID HEMORRHAGE DRUGS MARKET, BY DRUG CLASS, 2016-2023 ($THOUSAND)

TABLE 24. ASIA-PACIFIC ANEURYSMAL SUBARACHNOID HEMORRHAGE DRUGS MARKET, BY COUNTRY, 2016-2023 ($THOUSAND)

TABLE 25. JAPAN ANEURYSMAL SUBARACHNOID HEMORRHAGE DRUGS MARKET, BY DRUG CLASS, 2016-2023 ($THOUSAND)

TABLE 26. CHINA ANEURYSMAL SUBARACHNOID HEMORRHAGE DRUGS MARKET, BY DRUG CLASS, 2016-2023 ($THOUSAND)

TABLE 27. AUSTRALIA ANEURYSMAL SUBARACHNOID HEMORRHAGE DRUGS MARKET, BY DRUG CLASS, 2016-2023 ($THOUSAND)

TABLE 28. INDIA ANEURYSMAL SUBARACHNOID HEMORRHAGE DRUGS MARKET, BY DRUG CLASS, 2016-2023 ($THOUSAND)

TABLE 29. SOUTH KOREA ANEURYSMAL SUBARACHNOID HEMORRHAGE DRUGS MARKET, BY DRUG CLASS, 2016-2023 ($THOUSAND)

TABLE 30. REST OF ASIA-PACIFIC ANEURYSMAL SUBARACHNOID HEMORRHAGE DRUGS MARKET, BY DRUG CLASS, 2016-2023 ($THOUSAND)

TABLE 31. ASIA-PACIFIC ANEURYSMAL SUBARACHNOID HEMORRHAGE DRUGS MARKET, BY DRUG CLASS, 2016-2023 ($THOUSAND)

TABLE 32. ASIA-PACIFIC ANEURYSMAL SUBARACHNOID HEMORRHAGE DRUGS MARKET, BY COUNTRY, 2016-2023 ($THOUSAND)

TABLE 33. BRAZIL ANEURYSMAL SUBARACHNOID HEMORRHAGE DRUGS MARKET, BY DRUG CLASS, 2016-2023 ($THOUSAND)

TABLE 34. SAUDI ARABIA ANEURYSMAL SUBARACHNOID HEMORRHAGE DRUGS MARKET, BY DRUG CLASS, 2016-2023 ($THOUSAND)

TABLE 35. SOUTH AFRICA ANEURYSMAL SUBARACHNOID HEMORRHAGE DRUGS MARKET, BY DRUG CLASS, 2016-2023 ($THOUSAND)

TABLE 36. REST OF LAMEA ANEURYSMAL SUBARACHNOID HEMORRHAGE DRUGS MARKET, BY DRUG CLASS, 2016-2023 ($THOUSAND)

TABLE 37. LAMEA ANEURYSMAL SUBARACHNOID HEMORRHAGE DRUGS MARKET, BY DRUG CLASS, 2016-2023 ($THOUSAND)

TABLE 38. ARBOR: COMPANY SNAPSHOT

TABLE 39. ARBOR: PRODUCT SEGMENTS

TABLE 40. ARBOR: PRODUCT PORTFOLIO

TABLE 41. EDGE THERAPEUTICS: COMPANY SNAPSHOT

TABLE 42. EDGE THERAPEUTICS: PRODUCT PORTFOLIO

TABLE 43. J&J: COMPANY SNAPSHOT

TABLE 44. J&J: OPERATING SEGMENTS

TABLE 45. J&J: PRODUCT PORTFOLIO

TABLE 46. MYLAN: COMPANY SNAPSHOT

TABLE 47. MYLAN: OPERATING SEGMENTS

TABLE 48. MYLAN: PRODUCT PORTFOLIO

TABLE 49. OREXO: COMPANY SNAPSHOT

TABLE 50. OREXO: PRODUCT PORTFOLIO

TABLE 51. PFIZER: COMPANY SNAPSHOT

TABLE 52. PFIZER: OPERATING SEGMENTS

TABLE 53. PFIZER: PRODUCT PORTFOLIO

TABLE 54. PURDUE PHARMA: COMPANY SNAPSHOT

TABLE 55. PURDUE PHARMA: PRODUCT PORTFOLIO

TABLE 56. PHARMAXIS: COMPANY SNAPSHOT

TABLE 57. PHARMAXIS: OPERATING SEGMENTS

TABLE 58. PHARMAXIS: PRODUCT PORTFOLIO

TABLE 59. SUN PHARMA: COMPANY SNAPSHOT

TABLE 60. SUN PHARMA: PRODUCT PORTFOLIO

TABLE 61. TEVA: COMPANY SNAPSHOT

TABLE 62. TEVA: OPERATING SEGMENTS

TABLE 63. TEVA: PRODUCT PORTFOLIO

List of Figures

  • FIGURE 01. MARKET SEGMENTATION

FIGURE 02. TOP INVESTMENT POCKETS

FIGURE 03. TOP PLAYER POSITIONING, 2016

FIGURE 04. IMPACT ANALYSES

FIGURE 05. COMPARATIVE ANALYSIS OF OPIOID ANALGESICS MARKET REVENUE, BY COUNTRY, 2016 & 2023(%)

FIGURE 06. COMPARATIVE ANALYSIS OF CALCIUM CHANNEL BLOCKERS MARKET REVENUE, BY COUNTRY, 2016 & 2023(%)

FIGURE 07. COMPARATIVE ANALYSIS OF ANTICONVULSANTS MARKET REVENUE, BY COUNTRY, 2016 & 2023(%)

FIGURE 08. COMPARATIVE ANALYSIS OF STOOL SOFTENERS MARKET REVENUE, BY COUNTRY, 2016 & 2023(%)

FIGURE 09. COMPARATIVE ANALYSIS OF OSMOTIC AGENTS/DIURETICS MARKET REVENUE, BY COUNTRY, 2016 & 2023(%)

FIGURE 10. COMPARATIVE ANALYSIS OF OTHER DRUGS MARKET REVENUE, BY COUNTRY, 2016 & 2023(%)

FIGURE 11. J&J: NET SALES, 2015-2017 ($MILLION)

FIGURE 12. J&J: REVENUE SHARE BY SEGMENT, 2017 (%)

FIGURE 13. J&J: REVENUE SHARE BY GEOGRAPHY, 2017 (%)

FIGURE 14. MYLAN: NET SALES, 2015-2017 ($MILLION)

FIGURE 15. MYLAN: REVENUE SHARE BY GEOGRAPHY, 2017 (%)

FIGURE 16. OREXO: NET SALES, 2015-2017 ($MILLION)

FIGURE 17. OREXO: REVENUE SHARE BY PRODUCT, 2017 (%)

FIGURE 18. OREXO: REVENUE SHARE BY GEOGRAPHY, 2017 (%)

FIGURE 19. PFIZER: NET SALES, 2015-2017 ($MILLION)

FIGURE 20. PFIZER: REVENUE SHARE BY SEGMENT, 2017 (%)

FIGURE 21. PFIZER: REVENUE SHARE BY GEOGRAPHY, 2017 (%)

FIGURE 22. PHARMAXIS: NET SALES, 2015-2017 ($MILLION)

FIGURE 23. PHARMAXIS: REVENUE SHARE BY SEGMENT, 2017 (%)

FIGURE 24. SUN PHARMA: NET SALES, 2015-2017 ($MILLION)

FIGURE 25. SUN PHARMA: REVENUE SHARE BY BUSINESS UNITS, 2017 (%)

FIGURE 26. SUN PHARMA: REVENUE SHARE BY GEOGRAPHY, 2017 (%)

FIGURE 27. TEVA: NET SALES, 2015-2017 ($MILLION)

FIGURE 28. TEVA: REVENUE SHARE BY SEGMENT, 2017 (%)

FIGURE 29. TEVA: REVENUE SHARE BY GEOGRAPHY, 2017 (%)

目次
Product Code: LI 184602

Aneurysmal subarachnoid hemorrhage (aSAH) is a condition wherein a brain aneurysm ruptures, resulting in bleeding in the subarachnoid space. In severe cases, bleeding may cause brain damage, leading to paralysis or coma, and even death. The National Institutes of Health (NIH) has stated that aneurysmal subarachnoid hemorrhage (SAH) is a worldwide health burden, with high fatality and permanent disability rates.

The global aneurysmal subarachnoid hemorrhage drugs market was valued at $160,269 thousand in 2016, and is estimated to reach $206,675 thousand by 2023, growing at a CAGR of 3.6% from 2017 to 2023. The major factors driving the global aneurysmal subarachnoid hemorrhage market are rise in prevalence of diseases such as stroke and hypertension, and surge in geriatric population. In addition, lifestyle modifications, such as increased alcohol consumption and smoking, further increase the risk for aSAH, which in turn stimulates the market growth. However, the associated side effects of drugs and medication taken during the treatment of aneurysmal subarachnoid hemorrhage restrain the market growth. Furthermore, the growth in awareness about the treatment of the aSAH is expected to provide numerous opportunities for the market growth in future.

The global aneurysmal subarachnoid hemorrhage market is segmented based on drug class and region. Based on drug class, the market is segmented into opioid analgesic, calcium channel blocker, anticonvulsant, stool softener, osmotic agent/diuretic, and other drugs. Based on region, the market is analyzed across North America, Europe, Asia-Pacific, and LAMEA.

The key players operating in this market are Arbor Pharmaceuticals Inc., Edge Therapeutics, Inc., Johnson & Johnson (Actelion Pharmaceuticals Ltd.), Mylan N.V., Orexo AB, Pfizer Inc., Purdue Pharma L.P., Pharmaxis, Ltd., Sun Pharmaceutical Industries Ltd., and Teva Pharmaceutical Industries Ltd. (Cephalon, Inc.).

KEY BENEFITS

  • This report provides an extensive analysis of the current and emerging trends, and dynamics in the global aneurysmal subarachnoid hemorrhage drugs market to identify the prevailing opportunities.
  • It presents a competitive landscape of the global market to predict the market scenario across geographies.
  • A comprehensive analysis of factors that drive and restrict the market growth is provided.
  • The region- and country-wise analyses are provided to understand the market trends and dynamics.

KEY MARKET SEGMENTS

By Drug Class

  • Opioid Analgesic
  • Calcium Channel Blocker
  • Anticonvulsant
  • Stool Softener
  • Osmotic Agent
  • Other Drugs

By Region

  • North America *U.S.
  • Canada
  • Mexico
  • Europe *Germany
  • France
  • UK
  • Italy
  • Spain
  • Rest of Europe
  • Asia-Pacific *Japan
  • China
  • India
  • Australia
  • South Korea
  • Rest of Asia-Pacific
  • LAMEA *Brazil
  • Saudi Arabia
  • South Africa
  • Rest of LAMEA

The key players profiled in this report are as follows:

  • Arbor Pharmaceuticals Inc.
  • Edge Therapeutics, Inc.
  • Johnson & Johnson (Actelion Pharmaceuticals Ltd.)
  • Mylan N.V.
  • Orexo AB
  • Pfizer Inc.
  • Purdue Pharma L.P.
  • Pharmaxis, Ltd.
  • Sun Pharmaceutical Industries Ltd.
  • Teva Pharmaceutical Industries Ltd. (Cephalon, Inc.)

Table of Contents

CHAPTER 1: INTRODUCTION

  • 1.1. Report description
  • 1.2. Key benefits
  • 1.3. Key market segments
  • 1.4. Research methodology
    • 1.4.1. Secondary research
    • 1.4.2. Primary research
    • 1.4.3. Analyst tools & models

CHAPTER 2: EXECUTIVE SUMMARY

  • 2.1. Key findings
  • 2.2. CXO perspective

CHAPTER 3: MARKET OVERVIEW

  • 3.1. Market definition and scope
  • 3.2. Key findings
    • 3.2.1. Top investment pockets
  • 3.3. Top player positioning, 2016
  • 3.4. Market dynamics
    • 3.4.1. Drivers
      • 3.4.1.1. Rising geriatric population
      • 3.4.1.2. Increasing prevalence of stroke and hypertension
      • 3.4.1.3. Lifestyle modifications which increase the risk of aSAH
    • 3.4.2. Restraints
      • 3.4.2.1. Side effects of the drugs
    • 3.4.3. Opportunities
      • 3.4.3.1. Need for growing awareness about the treatment of aSAH
    • 3.4.4. Impact analyses

CHAPTER 4: ANEURYSMAL SUBARACHNOID HEMORRHAGE DRUGS MARKET, BY DRUG CLASS

  • 4.1. Overview
    • 4.1.1. Patients treated, by drug class
    • 4.1.2. Market size and forecast
  • 4.2. Opioid analgesics
    • 4.2.1. Key market trends, growth factors & opportunities
    • 4.2.2. Market size and forecast by region
    • 4.2.3. Market analysis by country
  • 4.3. Calcium channel blockers
    • 4.3.1. Key market trends, growth factors & opportunities
    • 4.3.2. Market size and forecast by region
    • 4.3.3. Market analysis by country
  • 4.4. Anticonvulsants
    • 4.4.1. Key market trends, growth factors & opportunities
    • 4.4.2. Market size and forecast by region
    • 4.4.3. Market analysis by country
  • 4.5. Stool softeners
    • 4.5.1. Key market trends, growth factors & opportunities
    • 4.5.2. Market size and forecast by region
    • 4.5.3. Market analysis by country
  • 4.6. Osmotic agents/diuretics
    • 4.6.1. Key market trends, growth factors & opportunities
    • 4.6.2. Market size and forecast by region
    • 4.6.3. Market analysis by country
  • 4.7. Other drugs
    • 4.7.1. Key market trends, growth factors & opportunities
    • 4.7.2. Market size and forecast by region
    • 4.7.3. Market analysis by country

CHAPTER 5: ANEURYSMAL SUBARACHNOID HEMORRHAGE DRUGS MARKET, BY REGION

  • 5.1. Overview
    • 5.1.1. Market size and forecast
  • 5.2. North America
    • 5.2.1. Key market trends, growth factors & opportunities
    • 5.2.2. Market size and forecast by country
      • 5.2.2.1. U.S.
      • 5.2.2.1.1. U.S. aneurysmal subarachnoid hemorrhage market, by drug class
      • 5.2.2.2. Canada
      • 5.2.2.2.1. Canada aneurysmal subarachnoid hemorrhage market, by drug class
      • 5.2.2.3. Mexico
      • 5.2.2.3.1. Mexico aneurysmal subarachnoid hemorrhage market, by drug class
    • 5.2.3. North America market size and forecast by drug class
  • 5.3. Europe
    • 5.3.1. Key market trends, growth factors & opportunities
    • 5.3.2. Market size and forecast by country
      • 5.3.2.1. Germany
      • 5.3.2.1.1. Germany aneurysmal subarachnoid hemorrhage market, by drug class
      • 5.3.2.2. France
      • 5.3.2.2.1. France aneurysmal subarachnoid hemorrhage market, by drug class
      • 5.3.2.3. UK
      • 5.3.2.3.1. UK aneurysmal subarachnoid hemorrhage market, by drug class
      • 5.3.2.4. Italy
      • 5.3.2.4.1. Italy aneurysmal subarachnoid hemorrhage market, by drug class
      • 5.3.2.5. Spain
      • 5.3.2.5.1. Spain aneurysmal subarachnoid hemorrhage market, by drug class
      • 5.3.2.6. Rest of Europe
      • 5.3.2.6.1. Rest of Europe aneurysmal subarachnoid hemorrhage market, by drug class
    • 5.3.3. Europe market size and forecast by drug class
  • 5.4. Asia-Pacific
    • 5.4.1. Key market trends, growth factors & opportunities
    • 5.4.2. Market size and forecast by country
      • 5.4.2.1. Japan
      • 5.4.2.1.1. Japan aneurysmal subarachnoid hemorrhage market, by drug class
      • 5.4.2.2. China
      • 5.4.2.2.1. China aneurysmal subarachnoid hemorrhage market, by drug class
      • 5.4.2.3. Australia
      • 5.4.2.3.1. Australia aneurysmal subarachnoid hemorrhage market, by drug class
      • 5.4.2.4. India
      • 5.4.2.4.1. India aneurysmal subarachnoid hemorrhage market, by drug class
      • 5.4.2.5. South Korea
      • 5.4.2.5.1. South Korea aneurysmal subarachnoid hemorrhage market, by drug class
      • 5.4.2.6. Rest of Asia-Pacific
      • 5.4.2.6.1. Rest of Asia-Pacific aneurysmal subarachnoid hemorrhage market, by drug class
    • 5.4.3. Asia-Pacific market size and forecast by drug class
  • 5.5. LAMEA
    • 5.5.1. Key market trends, growth factors & opportunities
    • 5.5.2. Market size and forecast by country
      • 5.5.2.1. Brazil
      • 5.5.2.1.1. Brazil aneurysmal subarachnoid hemorrhage market, by drug class
      • 5.5.2.2. Saudi Arabia
      • 5.5.2.2.1. Saudi Arabia aneurysmal subarachnoid hemorrhage market, by drug class
      • 5.5.2.3. South Africa
      • 5.5.2.3.1. South Africa aneurysmal subarachnoid hemorrhage market, by drug class
      • 5.5.2.4. Rest of LAMEA
      • 5.5.2.4.1. Rest of LAMEA aneurysmal subarachnoid hemorrhage market, by drug class
    • 5.5.3. LAMEA market size and forecast by drug class

CHAPTER 6: COMPANY PROFILE

  • 6.1. Arbor Pharmaceuticals Inc.
    • 6.1.1. Company overview
    • 6.1.2. Company snapshot
    • 6.1.3. Operating business segments
    • 6.1.4. Product portfolio
    • 6.1.5. Key strategic moves and developments
  • 6.2. Edge Therapeutics, Inc.
    • 6.2.1. Company overview
    • 6.2.2. Company snapshot
    • 6.2.3. Product portfolio
    • 6.2.4. Business performance
  • 6.3. Johnson & Johnson (Actelion Pharmaceuticals Ltd.)
    • 6.3.1. Company overview
    • 6.3.2. Company snapshot
    • 6.3.3. Operating business segments
    • 6.3.4. Product portfolio
    • 6.3.5. Business performance
  • 6.4. Mylan N.V.
    • 6.4.1. Company overview
    • 6.4.2. Company snapshot
    • 6.4.3. Operating business segments
    • 6.4.4. Product portfolio
    • 6.4.5. Business performance
  • 6.5. Orexo AB
    • 6.5.1. Company overview
    • 6.5.2. Company snapshot
    • 6.5.3. Product portfolio
    • 6.5.4. Business performance
    • 6.5.5. Key strategic moves and developments
  • 6.6. Pfizer Inc.
    • 6.6.1. Company overview
    • 6.6.2. Company snapshot
    • 6.6.3. Operating business segments
    • 6.6.4. Product portfolio
    • 6.6.5. Business performance
  • 6.7. Purdue Pharma L.P.
    • 6.7.1. Company overview
    • 6.7.2. Company snapshot
    • 6.7.3. Product portfolio
    • 6.7.4. Key strategic moves and developments
  • 6.8. Pharmaxis, Ltd.
    • 6.8.1. Company overview
    • 6.8.2. Company snapshot
    • 6.8.3. Operating business segments
    • 6.8.4. Product portfolio
    • 6.8.5. Business performance
  • 6.9. Sun Pharmaceutical Industries Ltd.
    • 6.9.1. Company overview
    • 6.9.2. Company snapshot
    • 6.9.3. Operating business segments
    • 6.9.4. Product portfolio
    • 6.9.5. Business performance
  • 6.10. Teva Pharmaceutical Industries Ltd. (Cephalon, Inc.)
    • 6.10.1. Company overview
    • 6.10.2. Company snapshot
    • 6.10.3. Operating business segments
    • 6.10.4. Product portfolio
    • 6.10.5. Business performance